Sanofi, a French pharma giant, has posted satisfactory performance
during the third quarter ended September 2014 and its net profit
increased by 9.3 per cent to € 2,716 million from €2,484 million in the
corresponding period of last year. Its net sales grew by 4.1 per cent to
€8,781 million from €8,432 million. EPS improved to €1.47 from €1.36 in
the last period. Its R&D expenditure declined by 3 per cent to
€1,146 million reflecting lower spend on oncology.
Christopher A Viehbacher, CEO, said, “We are pleased with our performance in the third quarter. We achieved solid business EPS growth driven by continued strong contribution from our growth platforms, allowing us to confirm 2014 outlook. Growth platforms reached over 78 per cent of sales and grew 10 per cent. We have recently seen a more challenging US diabetes price environment which will impact our diabetes sales throughout 2015, while growth platforms globally are expected to continue to show solid growth. At the same time, our pipeline delivered strong results, with the release of exciting phase III data for alirocumab and our Dengue vaccine, the entry of dupilumab in phase III as well as the FDA approval of Cerdelga and the licensing of Afrezza.”
Christopher A Viehbacher, CEO, said, “We are pleased with our performance in the third quarter. We achieved solid business EPS growth driven by continued strong contribution from our growth platforms, allowing us to confirm 2014 outlook. Growth platforms reached over 78 per cent of sales and grew 10 per cent. We have recently seen a more challenging US diabetes price environment which will impact our diabetes sales throughout 2015, while growth platforms globally are expected to continue to show solid growth. At the same time, our pipeline delivered strong results, with the release of exciting phase III data for alirocumab and our Dengue vaccine, the entry of dupilumab in phase III as well as the FDA approval of Cerdelga and the licensing of Afrezza.”
No comments:
Post a Comment